A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration

Drug Metabolism and Disposition

Volumn 27, Issue 8, 1999, Pages 855-859

  Wang, Yunxia ^a   Roy, Amit ^b   Sun, Lei ^a   Lau, Chyan E ^a  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM;

ANIMAL EXPERIMENT; ARTICLE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; INTRAVENOUS DRUG ADMINISTRATION; LIVER METABOLISM; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ALGORITHMS; ALPRAZOLAM; ANIMALS; ANTI-ANXIETY AGENTS; AREA UNDER CURVE; HALF-LIFE; INJECTIONS, INTRAVENOUS; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0004580383     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Akaike HA (1974) A new look at the statistical model identification. IEEE Trans Automatic Control 19:716-723.
2. Charman WN, Rogge MC, Boddy AW, Barr WH and Berger BM (1993) Absorption of Danazol after administration to different sites of the gastrointestinal tract and the relationship to single-and double-peak phenomena in the plasma profiles. J Clin Pharmacol 33:1207-1213.
3. Dawson GW, Jue SG and Brogden RN (1984) Alprazolam. Drugs 27:132-147.
4. Fargeas MJ, Fioramonti J and Bueno L (1984) Time-related effects of benzodiazepines on intestinal motility in conscious dogs. J Pharm Pharmacol 36:130-132.
5. Fawcett JA and Kravitz HM (1982) Alprazolam. Pharmacotherapy 2:243-254.
6. Gabrielsson J and Weiner D (1997) Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications, 2nd ed., Swedish Pharmaceutical Press, Stockholm, Sweden.
7. Garzone PD and Kroboth PD (1989) Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 16:337-364.
8. Greenblatt DJ, Divoll M, Abernethy DR, Ochs HR and Shader RI (1983) Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 8:233-252.
9. Jin LY and Lau CE (1994) Determination of alprazolam and its major metabolites in serum microsamples by HPLC and its application to pharmacokinetics in rats. J Chromatogr 654:77-83.
10. Koga Y, Sato S, Sodeyama N, Takahashi M, Kato M, Iwatsuki N and Hashimoto Y (1992) Comparison of the relaxant effects of diazepam, flunitrazepam and midazolam on airway smooth muscle. Br J Anaesth 69:65-69.
11. Lau CE and Heatherington AC (1997) Pharmacokinetic-pharmacodynamic modeling of stimulatory and sedative effects of alprazolam: Timing performance deficits. J Pharmacol Exp Ther 283:1119-1129.
12. Lau CE, Ma F, Wang Y and Smith C (1996) Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: Relating DRL performance to pharmacokinetics. Psychopharmacology 126:241-248.
13. Lau CE and Wang J (1996) Alprazolam, caffeine and their interaction: Relating DRL performance to pharmacokinetics. Psychopharmacology 126:115-124.
14. Lau CE, Wang Y and Falk JL (1997a) Differential reinforcement of low rate performance, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling: Independent interaction of alprazolam and caffeine. J Pharmacol Exp Ther 281:1013-1029.
15. Lau CE, Wang Y and Falk JL (1997b) Independent interaction of alprazolam and caffeine under chronic dose regimens on differential reinforcement of low rate (DRL 45-s) performance.Psychopharmacology 134:277-286.
16. Oberle RL and Amidon GL (1987) The influence of gastric emptying and intestinal transit rates on the plasma level curve of cimetidine: An explanation for the double peak phenomenon. J Pharmacokinet Biopharm 15:529-544.
17. Owens MJ, Vargas MA, Knight DL and Nemeroff CB (1991) The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: Acute time course, chronic treatment and abrupt withdrawal. J Pharmacol Exp Ther 258:349-356.
18. Piquette-Miller M and Jamali F (1997) Pharmacokinetics and multiple peaking of acebutolol enantimoers in rats. Biopharm Drug Dispos 18:543-556.
19. Plusquellec Y, Campistron G, Staveris S, Barre J, Jung L, Tillement JP and Houin G (1987) A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: A double-site model for drug absorption. J Pharmacokinet Biopharm 15:225-239.
20. SAAM II (1997) User Guide. SAAM Institute, University of Washington, Seattle, WA.
21. Sethy VH and Harris DW (1982) Determination of biological activity of alprazolam, triazolam, and their metabolites. J Pharm Pharmacol 34:115-116.
22. Smith RB, Kroboth PD, Vanderlugt JT, Phillips JP and Juhl RP (1984) Pharmacokinetics and pharmacodynamics of alprazolam after oral and i.v. administration. Psychopharmacology 84:452-456.
23. Veng-Pedersen P (1980) Pharmacokinetics and bioavailability of cimetidine in humans. J Pharm Sci 75:394-398.
24. Wagner JG (1984) Unusual pharmacokinetics, unusual pharmacokinetics, In Pharmacokinetics: A Modem View (Benet LZ, Levy G and Ferraiolo BL eds) pp 173-189, Plenum Press, New York.